| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.EJCA.2012.02.057 |
| P698 | PubMed publication ID | 22446022 |
| P50 | author | Carsten Bokemeyer | Q1045499 |
| Eric Van Cutsem | Q37068027 | ||
| Claus-Henning Köhne | Q37068153 | ||
| Fortunato Ciardiello | Q43184447 | ||
| P2093 | author name string | Ilhan Celik | |
| Philippe Rougier | |||
| Michael Schlichting | |||
| Steffen Heeger | |||
| P433 | issue | 10 | |
| P921 | main subject | cetuximab | Q420296 |
| chemotherapy | Q974135 | ||
| colorectal cancer | Q188874 | ||
| colorectal carcinoma | Q25493920 | ||
| metastatic colon cancer | Q108566365 | ||
| P304 | page(s) | 1466-1475 | |
| P577 | publication date | 2012-03-23 | |
| P1433 | published in | European Journal of Cancer | Q332260 |
| P1476 | title | Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials | |
| P478 | volume | 48 |
| Q38584379 | A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance |
| Q26775711 | A Comprehensive Review of Clinical Trials on EGFR Inhibitors Such as Cetuximab and Panitumumab as Monotherapy and in Combination for Treatment of Metastatic Colorectal Cancer |
| Q38674714 | A Review of Clinical Studies and Practical Guide for the Administration of Triplet Chemotherapy Regimens with Bevacizumab in First-line Metastatic Colorectal Cancer |
| Q35187723 | A mutant BRAF V600E-specific immunohistochemical assay: correlation with molecular mutation status and clinical outcome in colorectal cancer |
| Q90843197 | A practical guide to biomarkers for the evaluation of colorectal cancer |
| Q34580450 | A prospective multicenter phase II study evaluating multimodality treatment of patients with peritoneal carcinomatosis arising from appendiceal and colorectal cancer: the COMBATAC trial |
| Q38943220 | Advances in Biomarkers: Going Beyond the Carcinoembryonic Antigen. |
| Q26751344 | Advances in targeted and immunobased therapies for colorectal cancer in the genomic era |
| Q53490424 | An Unusual Combination: KRAS and BRAF Co-mutated Metastatic Colorectal Cancer. |
| Q38650454 | Anti-EGFR monoclonal antibody panitumumab for the treatment of patients with metastatic colorectal cancer: an overview of current practice and future perspectives. |
| Q97525750 | Anti-EGFR therapy in metastatic colorectal cancer: mechanisms and potential regimens of drug resistance |
| Q37611840 | Anti-tumor effects of an oncolytic adenovirus expressing hemagglutinin-neuraminidase of Newcastle disease virus in vitro and in vivo |
| Q38214511 | Antibodies directed against receptor tyrosine kinases: current and future strategies to fight cancer |
| Q36321184 | Antiepidermal growth factor receptor monoclonal antibodies: applications in colorectal cancer |
| Q58053523 | Are Gene Signatures Ready for Use in the Selection of Patients for Adjuvant Treatment? |
| Q36334196 | Assessment of frequency and severity of hypomagnesemia in patients with metastatic colorectal cancer treated with cetuximab, with a review of the literature. |
| Q59329181 | Association Between c-Myc and Colorectal Cancer Prognosis: A Meta-Analysis |
| Q34759064 | Association between molecular subtypes of colorectal cancer and patient survival |
| Q39703372 | Association of CpG island methylator phenotype and EREG/AREG methylation and expression in colorectal cancer. |
| Q55090775 | BRAF Inhibitors for BRAF V600E Mutant Colorectal Cancers: Literature Survey and Case Report. |
| Q97525759 | BRAF and KRAS mutations in metastatic colorectal cancer: future perspectives for personalized therapy |
| Q38652005 | BRAF in metastatic colorectal cancer: the future starts now. |
| Q26772276 | BRAF mutant colorectal cancer as a distinct subset of colorectal cancer: clinical characteristics, clinical behavior, and response to targeted therapies |
| Q47767987 | BRAF mutant colorectal cancer: prognosis, treatment, and new perspectives |
| Q40823445 | BRAF mutation may have different prognostic implications in early- and late-stage colorectal cancer |
| Q36807082 | BRAF mutations in colorectal cancer: clinical relevance and role in targeted therapy |
| Q38953687 | BRAF-Mutated Colorectal Cancer: What Is the Optimal Strategy for Treatment? |
| Q89736584 | Be Active or Not: the Relative Contribution of Active and Passive Tumor Targeting of Nanomaterials |
| Q38238740 | Beyond KRAS: Predictive factors of the efficacy of anti-EGFR monoclonal antibodies in the treatment of metastatic colorectal cancer. |
| Q55518414 | Biologic Response of Colorectal Cancer Xenograft Tumors to Sequential Treatment with Panitumumab and Bevacizumab. |
| Q37114675 | Biomarker in Colorectal Cancer. |
| Q91754859 | Biomarker-guided therapy for colorectal cancer: strength in complexity |
| Q60046390 | Biomarkers in colorectal cancer: Current clinical utility and future perspectives |
| Q37609130 | Biomarkers in precision therapy in colorectal cancer. |
| Q26766535 | Biomarkers predicting resistance to epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer with wild-type KRAS |
| Q34052270 | Biweekly cetuximab and first-line chemotherapy in chinese patients with k-ras wild-type colorectal cancers |
| Q37706705 | Building personalized treatment plans for early-stage colorectal cancer patients |
| Q27010961 | Cancer concepts and principles: primer for the interventional oncologist-part II |
| Q33580500 | Cetuximab-induced MET activation acts as a novel resistance mechanism in colon cancer cells |
| Q47164059 | Challenges and future of biomarker tests in the era of precision oncology: Can we rely on immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH) to select the optimal patients for matched therapy? |
| Q92451360 | Characteristics of BRAF V600E Mutant, Deficient Mismatch Repair/Proficient Mismatch Repair, Metastatic Colorectal Cancer: A Multicenter Series of 287 Patients |
| Q37530472 | Chemotherapy plus bevacizumab versus chemotherapy plus cetuximab as first-line treatment for patients with metastatic colorectal cancer: Results of a registry-based cohort analysis. |
| Q54288887 | Circulating tumor cells as a longitudinal biomarker in patients with advanced chemorefractory, RAS-BRAF wild-type colorectal cancer receiving cetuximab or panitumumab. |
| Q38800475 | Clinical Applications of Liquid Biopsies in Gastrointestinal Oncology |
| Q55385744 | Clinical activity and tolerability of FOLFIRI and cetuximab in elderly patients with metastatic colorectal cancer in the CAPRI-GOIM first-line trial. |
| Q97884672 | Clinical complete regression after local radiotherapy combined with chemotherapy for stage IV rectal cancer: A case report |
| Q92514791 | Clinicopathologic features and prognostic value of KRAS, NRAS and BRAF mutations and DNA mismatch repair status: A single-center retrospective study of 1,834 Chinese patients with Stage I-IV colorectal cancer |
| Q42690646 | Clinicopathologic features and treatment efficacy of Chinese patients with BRAF-mutated metastatic colorectal cancer: a retrospective observational study |
| Q28647615 | Colorectal Cancer Classification and Cell Heterogeneity: A Systems Oncology Approach |
| Q57178427 | Colorectal Liver Metastases: Does the Future of Precision Medicine Lie in Genetic Testing? |
| Q90834049 | Colorectal cancer |
| Q38124901 | Colorectal cancer diagnostics: biomarkers, cell-free DNA, circulating tumor cells and defining heterogeneous populations by single-cell analysis |
| Q26768427 | Colorectal cancer tumour markers and biomarkers: Recent therapeutic advances |
| Q47303076 | Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy |
| Q27853216 | Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer. |
| Q36051757 | Comet assay measures of DNA damage as biomarkers of irinotecan response in colorectal cancer in vitro and in vivo |
| Q44193651 | Comparison of COBAS 4800 KRAS, TaqMan PCR and high resolution melting PCR assays for the detection of KRAS somatic mutations in formalin-fixed paraffin embedded colorectal carcinomas. |
| Q48272442 | Comparison of cetuximab to bevacizumab as the first-line bio-chemotherapy for patients with metastatic colorectal cancer: superior progression-free survival is restricted to patients with measurable tumors and objective tumor response--a retrospecti |
| Q41918653 | Conversion Therapy Using mFOLFOX6 With Panitumumab for Unresectable Liver Metastases From Multiple Colorectal Cancers With Familial Adenomatous Polyposis |
| Q41116981 | Conversion to resection of liver metastases from colorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIV. |
| Q38810330 | Cost-effectiveness of cetuximab for colorectal cancer |
| Q38117718 | Cure for peritoneal metastases? An evidence-based review |
| Q93039741 | Current Development of Monoclonal Antibodies in Cancer Therapy |
| Q43492228 | Current and future biomarkers in colorectal cancer |
| Q90437250 | Current challenges in the implementation of precision oncology for the management of metastatic colorectal cancer |
| Q38538213 | Current controversies in the management of metastatic colorectal cancer |
| Q38241395 | Current opinion on optimal systemic treatment for metastatic colorectal cancer: outcome of the ACTG/AGITG expert meeting ECCO 2013. |
| Q38101612 | Current opinion on optimal treatment for colorectal cancer. |
| Q26740067 | Current targeted therapies in the treatment of advanced colorectal cancer: a review |
| Q34819493 | Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from colorectal cancer: a case-control study from a Chinese center |
| Q40428222 | Differential Radiographic Appearance of BRAF V600E-Mutant Metastatic Colorectal Cancer in Patients Matched by Primary Tumor Location |
| Q35773077 | Distinct gene expression profiles of proximal and distal colorectal cancer: implications for cytotoxic and targeted therapy. |
| Q43626555 | Does a higher response rate to systemic chemotherapy result in a higher resection rate in patients with initially unresectable colorectal liver metastases? |
| Q90190600 | EGFR Protein Expression in KRAS Wild-Type Metastatic Colorectal Cancer Is Another Negative Predictive Factor of the Cetuximab Therapy |
| Q35107670 | EGFR-directed antibodies increase the risk of severe infection in cancer patients |
| Q57758061 | ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making |
| Q38175833 | Effect of BRAF V600E mutation on tumor response of anti-EGFR monoclonal antibodies for first-line metastatic colorectal cancer treatment: a meta-analysis of randomized studies |
| Q37005364 | Effect of RAS status on anti-EGFR monoclonal antibodies + 5-FU infusion-based chemotherapy in first-line treatment of metastatic colorectal cancer: A meta-analysis |
| Q26777704 | Effectiveness and safety of monoclonal antibodies for metastatic colorectal cancer treatment: systematic review and meta-analysis |
| Q47870743 | Effects of metformin on colorectal cancer stem cells depend on alterations in glutamine metabolism |
| Q92088491 | Efficacy and safety of bevacizumab-based maintenance therapy in metastatic colorectal cancer: A meta-analysis |
| Q39694235 | Efficacy of cetuximab-based chemotherapy in metastatic colorectal cancer according to RAS and BRAF mutation subgroups: A meta-analysis |
| Q53548338 | Elucidating the prognostic significance of KRAS, NRAS, BRAF and PIK3CA mutations in Chinese patients with metastatic colorectal cancer. |
| Q52599786 | Emerging treatment options for BRAF-mutant colorectal cancer. |
| Q35828499 | Epidermal growth factor receptor mutation mediates cross-resistance to panitumumab and cetuximab in gastrointestinal cancer. |
| Q35834442 | Evaluation in usual practice of the bevacizumab-FOLFIRI combination for the first-line treatment of patients with unresectable metastatic colorectal cancer treated in 2006: focus on resected patients and oncogeriatrics: AVASTIN OUEST cohort of the O |
| Q28074285 | Evaluation of Cysteinyl Leukotriene Signaling as a Therapeutic Target for Colorectal Cancer |
| Q35102475 | Expanded RAS: refining the patient population |
| Q92231021 | Exploring the best treatment options for BRAF-mutant metastatic colon cancer |
| Q36287075 | Expression of pEGFR and pAKT as response-predictive biomarkers for RAS wild-type patients to anti-EGFR monoclonal antibodies in metastatic colorectal cancers |
| Q26798284 | Extended RAS analysis for anti-epidermal growth factor therapy in patients with metastatic colorectal cancer |
| Q35587176 | Extended RAS and BRAF Mutation Analysis Using Next-Generation Sequencing |
| Q52666988 | FOLFOX plus anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) is an effective first-line treatment for patients with RAS-wild left-sided metastatic colorectal cancer: A meta-analysis. |
| Q36857518 | Feasibility of proposed single-nucleotide polymorphisms as predictive markers for targeted regimens in metastatic colorectal cancer |
| Q55154019 | First Biologic Drug in the Treatment of RAS Wild-Type Metastatic Colorectal Cancer: Anti-EGFR or Bevacizumab? Results From a Meta-Analysis. |
| Q90450020 | First-line molecular therapies in the treatment of metastatic colorectal cancer - a literature-based review of phases II and III trials |
| Q64238010 | G12V Mutation is an Adverse Prognostic Factor of Chinese Gastric Cancer Patients |
| Q35137474 | Gain of ALK gene copy number may predict lack of benefit from anti-EGFR treatment in patients with advanced colorectal cancer and RAS-RAF-PI3KCA wild-type status |
| Q47673133 | Gastrointestinal Malignancy: Genetic Implications to Clinical Applications |
| Q95818304 | Genetic targeting of B-RafV600E affects survival and proliferation and identifies selective agents against BRAF-mutant colorectal cancer cells |
| Q91743984 | Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal Cancer |
| Q39023377 | Germline polymorphisms as biomarkers of tumor response in colorectal cancer patients treated with anti-EGFR monoclonal antibodies: a systematic review and meta-analysis. |
| Q35229101 | Global impact of KRAS mutation patterns in FOLFOX treated metastatic colorectal cancer |
| Q38894659 | HDAC Inhibition Overcomes Acute Resistance to MEK Inhibition in BRAF-Mutant Colorectal Cancer by Downregulation of c-FLIPL |
| Q33858231 | Heterogeneity in the colorectal primary tumor and the synchronous resected liver metastases prior to and after treatment with an anti-EGFR monoclonal antibody |
| Q36238965 | How many diseases are colorectal cancer? |
| Q60939319 | How the V600E Mutation Defines a Distinct Subgroup of Colorectal Cancer: Molecular and Clinical Implications |
| Q27026516 | How to select the optimal treatment for first line metastatic colorectal cancer |
| Q48034907 | Identification of a novel metabolic-related mutation (IDH1) in metastatic pancreatic cancer |
| Q27693248 | Identification of clinically relevant molecular subtypes in colorectal cancer: the dawning of a new era |
| Q35030421 | Identification of the angiogenic gene signature induced by EGF and hypoxia in colorectal cancer. |
| Q43439313 | Immunohistochemistry using the BRAF V600E mutation-specific monoclonal antibody VE1 is not a useful surrogate for genotyping in colorectal adenocarcinoma |
| Q57800147 | Impact of Delayed Addition of Anti-EGFR Monoclonal Antibodies on the Outcome of First-Line Therapy in Metastatic Colorectal Cancer Patients: a Retrospective Registry-Based Analysis |
| Q38183447 | Impact of cetuximab in current treatment of metastatic colorectal cancer. |
| Q90428458 | Improving patient selection for adjuvant therapy in high-risk renal cell carcinoma |
| Q48585692 | Incorporating BEAMing technology as a liquid biopsy into clinical practice for the management of colorectal cancer patients: an expert taskforce review |
| Q38545768 | Incorporating traditional and emerging biomarkers in the clinical management of metastatic colorectal cancer. |
| Q44069776 | Interpreting the clinical utility of a pharmacogenomic marker based on observational association studies |
| Q96166477 | Intra-arterial hepatic beads loaded with irinotecan (DEBIRI) with mFOLFOX6 in unresectable liver metastases from colorectal cancer: a Phase 2 study |
| Q35009259 | Intraoperative blood loss independently predicts survival and recurrence after resection of colorectal cancer liver metastasis |
| Q36936979 | Is early response by (18)F-2-fluoro-2-deoxy-D-glucose positron emission tomography-computed tomography a predictor of long-term outcome in patients with metastatic colorectal cancer? |
| Q55071072 | KRAS and BRAF mutations in anal carcinoma. |
| Q41136513 | KRAS as a predictor of poor prognosis and benefit from postoperative FOLFOX chemotherapy in patients with stage II and III colorectal cancer |
| Q27852414 | KRAS as prognostic biomarker in metastatic colorectal cancer patients treated with bevacizumab: a pooled analysis of 12 published trials |
| Q37495964 | KRAS early testing: consensus initiative and cost-effectiveness evaluation for metastatic colorectal patients in an Italian setting |
| Q90279899 | KRAS, NRAS, BRAF, HER2 and microsatellite instability in metastatic colorectal cancer - practical implications for the clinician |
| Q36889656 | KRAS-mutation status in relation to colorectal cancer survival: the joint impact of correlated tumour markers |
| Q44422760 | Landmark study raises the bar for interventional oncology |
| Q38783966 | MGMT in colorectal cancer: a promising component of personalized treatment |
| Q28076490 | Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer |
| Q27027648 | Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer |
| Q37481713 | Metastatic colorectal cancer-prolonging overall survival with targeted therapies |
| Q33654609 | Microenvironmental regulation of therapeutic response in cancer |
| Q37471795 | Microsatellite instability and B-type Raf proto-oncogene mutation in colorectal cancer: Clinicopathological characteristics and effects on survival |
| Q41175542 | Microvessel density and endothelial cell proliferation levels in colorectal liver metastases from patients given neo-adjuvant cytotoxic chemotherapy and bevacizumab |
| Q28070038 | Molecular Diagnostics for Precision Medicine in Colorectal Cancer: Current Status and Future Perspective |
| Q91599765 | Molecular Profiles Guide Colorectal Cancer Treatment |
| Q47439465 | Molecular basis for necitumumab inhibition of EGFR variants associated with acquired cetuximab resistance |
| Q64071667 | Molecular biomarkers and histological parameters impact on survival and response to first- line systemic therapy of metastatic colorectal cancer patients |
| Q59794745 | Molecular characterization and biomarker identification in colorectal cancer: Toward realization of the precision medicine dream |
| Q37642614 | Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitors. |
| Q38258269 | Molecular markers for colon diagnosis, prognosis and targeted therapy |
| Q38938329 | Molecular markers of prognosis and therapeutic targets in metastatic colorectal cancer. |
| Q26778296 | Molecular profiling in the treatment of colorectal cancer: focus on regorafenib |
| Q37525272 | Molecular spectrum of KRAS, NRAS, BRAF, PIK3CA, TP53, and APC somatic gene mutations in Arab patients with colorectal cancer: determination of frequency and distribution pattern. |
| Q64935738 | Molecular targeted therapy of BRAF-mutant colorectal cancer. |
| Q26828735 | Molecularly targeted drugs for metastatic colorectal cancer |
| Q35807573 | Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study. |
| Q35224224 | Multicenter phase II study of FOLFIRI plus bevacizumab after discontinuation of oxaliplatin-based regimen for advanced or recurrent colorectal cancer (CR0802) |
| Q26796348 | New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS? |
| Q26772277 | New therapeutic strategies for BRAF mutant colorectal cancers |
| Q57739115 | Noninvasive Biomarkers of Colorectal Cancer: Role in Diagnosis and Personalised Treatment Perspectives |
| Q38800472 | Novel Therapies in Development for Metastatic Colorectal Cancer |
| Q26769884 | Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential |
| Q38799963 | Novel investigational therapies for treating biliary tract carcinoma |
| Q37429996 | Observational study on quality of life, safety, and effectiveness of first-line cetuximab plus chemotherapy in KRAS wild-type metastatic colorectal cancer patients: the ObservEr Study |
| Q37231968 | Optimization of routine KRAS mutation PCR-based testing procedure for rational individualized first-line-targeted therapy selection in metastatic colorectal cancer |
| Q30235144 | Overall survival of patients with KRAS wild-type tumor treated with FOLFOX/FORFIRI±cetuximab as the first-line treatment for metastatic colorectal cancer: A meta-analysis |
| Q61816598 | Overcoming Intrinsic and Acquired Cetuximab Resistance in RAS Wild-Type Colorectal Cancer: An In Vitro Study on the Expression of HER Receptors and the Potential of Afatinib |
| Q38084846 | PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types |
| Q40235695 | PIK3CA Mutations Contribute to Acquired Cetuximab Resistance in Patients with Metastatic Colorectal Cancer. |
| Q31168985 | Palliative care and end-stage colorectal cancer management: the surgeon meets the oncologist |
| Q38167675 | Palliative treatment of metastatic colorectal cancer: what is the optimal approach? |
| Q38193195 | Panitumumab : leading to better overall survival in metastatic colorectal cancer? |
| Q38562067 | Panitumumab for the treatment of metastatic colorectal cancer: a review. |
| Q47134024 | Panitumumab use in metastatic colorectal cancer and patterns of RAS testing: results from a Europe-wide physician survey and medical records review |
| Q33947880 | Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/Alliance N0147 |
| Q43136720 | Performance of a novel KRAS mutation assay for formalin-fixed paraffin embedded tissues of colorectal cancer |
| Q33838073 | Peritoneal metastases of lower gastrointestinal tract origin:a comparative study of patient outcomes following cytoreduction and intraperitoneal chemotherapy |
| Q39453553 | Personalized and precision medicine: integrating genomics into treatment decisions in gastrointestinal malignancies |
| Q38232150 | Personalized oncology: genomic screening in phase 1. |
| Q26822817 | Personalized treatment for advanced colorectal cancer: KRAS and beyond |
| Q38296666 | Personalized treatment is better than one treatment fits all in the management of patients with mCRC: a consensus statement |
| Q36086845 | Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer |
| Q99635705 | Phase II study on first-line treatment of NIVolumab in combination with folfoxiri/bevacizumab in patients with Advanced COloRectal cancer RAS or BRAF mutated - NIVACOR trial (GOIRC-03-2018) |
| Q27853121 | Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients |
| Q38805790 | Potential biomarkers for anti-EGFR therapy in metastatic colorectal cancer |
| Q38271031 | Pragmatic issues in biomarker evaluation for targeted therapies in cancer |
| Q26795558 | Precision medicine in colorectal cancer: the molecular profile alters treatment strategies |
| Q26738655 | Predictive Biomarkers in Colorectal Cancer: From the Single Therapeutic Target to a Plethora of Options |
| Q37697540 | Predictive and prognostic biomarkers with therapeutic targets in advanced colorectal cancer. |
| Q90448739 | Preoperative chemotherapy in colorectal cancer patients with synchronous liver metastasis |
| Q38648300 | Present and future of metastatic colorectal cancer treatment: A review of new candidate targets |
| Q27015224 | Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies |
| Q41410508 | Prognostic Value of BRAF, PI3K, PTEN, EGFR Copy Number, Amphiregulin and Epiregulin Status in Patients with KRAS Codon 12 Wild-Type Metastatic Colorectal Cancer Receiving First-Line Chemotherapy with Anti-EGFR Therapy. |
| Q89529095 | Prognostic and Predictive Molecular Biomarkers for Colorectal Cancer: Updates and Challenges |
| Q36115580 | Prognostic and predictive biomarkers in metastatic colorectal cancer anti-EGFR therapy |
| Q38089641 | Promising biomarkers for predicting the outcomes of patients with KRAS wild-type metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: a systematic review with meta-analysis |
| Q35583697 | Prospective study of a molecular selection profile for RAS wild type colorectal cancer patients receiving irinotecan-cetuximab |
| Q33555345 | Protocol for Combined Analysis of FOXFIRE, SIRFLOX, and FOXFIRE-Global Randomized Phase III Trials of Chemotherapy +/- Selective Internal Radiation Therapy as First-Line Treatment for Patients With Metastatic Colorectal Cancer. |
| Q30967175 | RAS Mutations Beyond KRAS Exon 2: A Review and Discussion of Clinical Trial Data |
| Q28074175 | RAS and BRAF in metastatic colorectal cancer management |
| Q33648830 | RHBDD1 upregulates EGFR via the AP-1 pathway in colorectal cancer |
| Q37701607 | Radiolabeled novel mAb 4G1 for immunoSPECT imaging of EGFRvIII expression in preclinical glioblastoma xenografts |
| Q38376696 | Randomized Phase II Trial of Seribantumab in Combination With Paclitaxel in Patients With Advanced Platinum-Resistant or -Refractory Ovarian Cancer. |
| Q93040761 | Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer |
| Q39140763 | Rational combination of a MEK inhibitor, selumetinib, and the Wnt/calcium pathway modulator, cyclosporin A, in preclinical models of colorectal cancer |
| Q33624491 | Recent Advances in Targeting the EGFR Signaling Pathway for the Treatment of Metastatic Colorectal Cancer |
| Q26851075 | Recent applications of chemosensitivity tests for colorectal cancer treatment |
| Q90083939 | Response to Anti-EGFR Therapy in Patients with BRAF non-V600-Mutant Metastatic Colorectal Cancer |
| Q37542817 | Response to MLN8237 in pancreatic cancer is not dependent on RalA phosphorylation |
| Q36244599 | Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients. |
| Q38516244 | Role and mechanisms of resistance of epidermal growth factor receptor antagonists in the treatment of colorectal cancer. |
| Q49566155 | Role of Anti-Epidermal Growth Factor Receptor Therapy Compared with Anti-Vascular Endothelial Growth Factor Therapy for Metastatic Colorectal Cancer: an Update Meta-Analysis of Randomized Clinical Trials |
| Q37708010 | Role of cetuximab in first-line treatment of metastatic colorectal cancer |
| Q39051652 | Role of circulating free DNA in colorectal cancer |
| Q64067069 | SUVmax and metabolic tumor volume: surrogate image biomarkers of KRAS mutation status in colorectal cancer |
| Q26751035 | Serrated colorectal cancer: Molecular classification, prognosis, and response to chemotherapy |
| Q53164323 | Significance of FGF9 gene in resistance to anti-EGFR therapies targeting colorectal cancer: A subset of colorectal cancer patients with FGF9 upregulation may be resistant to anti-EGFR therapies. |
| Q87702900 | Significance of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer patients receiving Bevacizumab: a single institution experience |
| Q37548830 | Single agent panitumumab in KRAS wild-type metastatic colorectal cancer patients following cetuximab-based regimens: Clinical outcome and biomarkers of efficacy |
| Q28088693 | Standard chemotherapy with cetuximab for treatment of colorectal cancer |
| Q39949794 | Systemic treatment of liver metastases from colorectal cancer |
| Q92306520 | Targeted Therapy in Metastatic Colorectal Cancer: Current Standards and Novel Agents in Review |
| Q30862367 | Targeted therapies in metastatic colorectal cancer: a systematic review and assessment of currently available data |
| Q38652294 | Targeting BRAF aberrations in advanced colorectal carcinoma: from bench to bedside. |
| Q38239612 | Targeting BRAF mutant metastatic colorectal cancer: clinical implications and emerging therapeutic strategies |
| Q38390840 | Targeting EGFR in metastatic colorectal cancer beyond the limitations of KRAS status: alternative biomarkers and therapeutic strategies. |
| Q38241190 | Targeting angiogenesis and tumor microenvironment in metastatic colorectal cancer: role of aflibercept. |
| Q41922459 | Temsirolimus enhances the efficacy of cetuximab in colon cancer through a CIP2A-dependent mechanism. |
| Q90290671 | The Association of Baseline Serum Tumour Markers with Outcome of Patients with Metastatic Colorectal Cancer Treated with Anti-EGFR Monoclonal Antibodies in the First Line |
| Q38773904 | The EGFR-specific antibody cetuximab combined with chemotherapy triggers immunogenic cell death. |
| Q92193162 | The Evolving Biomarker Landscape for Treatment Selection in Metastatic Colorectal Cancer |
| Q38825575 | The Multidisciplinary Management of Colorectal Cancer: Present and Future Paradigms |
| Q38481038 | The distinctive molecular, pathological and clinical characteristics of BRAF-mutant colorectal tumors |
| Q89520785 | The evolving treatment paradigm for BRAF V600 mutant colorectal cancer |
| Q27852988 | The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis |
| Q34776118 | The prognostic role of BRAF mutation in metastatic colorectal cancer receiving anti-EGFR monoclonal antibodies: a meta-analysis |
| Q48266694 | The prognostic role of microsatellite instability, codon-specific KRAS, and BRAF mutations in colon cancer |
| Q37130603 | The role of personalized medicine in metastatic colorectal cancer: an evolving landscape |
| Q38181431 | Tissue-based biomarkers predicting outcomes in metastatic colorectal cancer: a review. |
| Q26827212 | Toward a Molecular Classification of Colorectal Cancer: The Role of BRAF |
| Q30239109 | Translating genomic profiling to gastrointestinal cancer treatment |
| Q34503734 | Treatment of colorectal liver metastases in Germany: a ten-year population-based analysis of 5772 cases of primary colorectal adenocarcinoma |
| Q34441837 | Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines update |
| Q54405775 | Ultra-deep sequencing confirms immunohistochemistry as a highly sensitive and specific method for detecting BRAF V600E mutations in colorectal carcinoma. |
| Q37606696 | Use of a High-Throughput Genotyping Platform (OncoMap) for RAS Mutational Analysis to Predict Cetuximab Efficacy in Patients with Metastatic Colorectal Cancer. |
| Q48263612 | Using Genome Sequence to Enable the Design of Medicines and Chemical Probes. |
| Q36341759 | Using Molecular Markers to Guide Therapy of Metastatic Colorectal Cancer |
| Q36561520 | VE1 immunohistochemistry predicts BRAF V600E mutation status and clinical outcome in colorectal cancer |
| Q36286704 | Vascular endothelial growth factor D expression is a potential biomarker of bevacizumab benefit in colorectal cancer |
| Q53581884 | [Molecular pathology of colorectal cancer]. |
Search more.